Medicilon Logo
search icon search icon language icon contact icon menu icon
Medicilon Logo
search icon close search icon language icon contact icon menu icon
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
Medicilon's News information
News information

Join Medicilon at the Discovery on Target (DOT) 2022

Page View:


Medicilon looks forward to meeting you from October 17-20 in Boston, MA. Medicilon is experienced with oncology drug in any preclinical phases, from hit-to-lead to IND. We provide integrated service strategies for sponsors’ oncology drug discovery and development pipelines. We aim to enhance every step in preclinical search and to deliver real time data.

Date: October 17-20, 2022

Location: Boston, MA

Medicilon Booth: 506

About Discovery on Target (DOT)

Discovery on Target (DOT) is an industrial preeminent event on novel drug targets and technologies for drug discovery professionals.  Discovery on Target (DOT) highlights advances in current and emerging “hot” targets and technologies, as well as target validation strategies for the discovery and development of novel therapeutic agents ranging from biologics to small molecules. The 20th Annual event brings back popular topics like PROTACs and RNA plus new programming on immunomodulation, antivirals, neurodegeneration targets, KRAS, and AI.


Medicilon Innovative Drug R&D Services

Antibody-Drug Conjugate (ADC)

Medicilon offers clients with a pool of payload drugs of various mechanisms and offers custom synthesis of payload drugs. Medicilon fully understands the complexity of ADA evaluation and offers our clients with comprehensive immunogenicity assays.

Proteolysis Targeting Chimera (PROTAC)

Medicilon gathers the popular POI ligands and multiple tissue types of E3 ligase ligands, in addition of established a linker library containing hundreds of linking molecules. Medicilon has established a complete PROTAC in vitro analysis platform.

mRNA Vaccine Bioanalysis Platform

Medicilon has provided comprehensive support and services for the safety and effectiveness evaluation of various new drugs and vaccines, specifically the research of LNP-mRNA drugs and vaccines.  We have accumulated rich experience on this technology; therefore, we establish the bioanalysis platform for mRNA vaccines. Based on the mechanism and characteristics of mRNA vaccines, Medicilon’s Bioanalysis Department has established an evaluation platform covering metabolism and biodistribution, key sequence domain antibodies and antiviral neutralizing antibody titers and the evaluation of effectiveness of cellular immune response.

AI R&D Innovation

As the first CRO stock on the Sci-tech Innovation Board, Medicilon is one of the companies that pay attention to AI technology in the industry at the beginning.  Currently, Medicilon uses deep neural network machine learning technology to construct a BTK inhibitor drug design model.  Medicilon also commits to establishing a molecular design and screening platform for BTK inhibitor drugs, launching “CRO+AI” to accelerate the development of new drugs.

Cellular Immunotherapies

Cellular immunotherapy has developed by leaps and bounds in recent years, providing a cure for many difficult-to-treat cancers.  With the continuous discovery of tumor targets and mechanisms, the track is still full of vitality and hope bringing new breakthroughs in tumor treatment and human welfare. Medicilon has built a one-stop research platform for the preclinical R&D of cellular immunotherapies, covering a variety of immunotherapy methods including CAR-T, TCR-T and CAR-NK. Using a wealth of animal models and a variety of advanced analysis techniques, comprehensively considering the characteristics of different research projects, Medicilon has completed numerous pre-clinical projects for clients worldwide.

Relevant newsRelevant news